National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 47 of 66
PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
NCT00088413
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
NCT00076102
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
NCT00085371
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
NCT00077350
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
NCT00089271
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
NCT00091117
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00089362
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
NCT00088374
Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
NCT00089349
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
NCT00091026
Cilengitide in Treating Patients With Acute Myeloid Leukemia
NCT00089388
Effect of Genetic Differences on Levels of Water Disinfection Byproducts in Blood After Showering
NCT00340535
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
NCT00089544
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
NCT00088855
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00088894
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
NCT00087074
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00054041
Effect of Tenofovir DF on Bone Metabolism in Children
NCT00088309
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00079430
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
NCT00080899
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
NCT00077428
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
NCT00089063
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00087373
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
NCT00086970
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
NCT00089076
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
NCT00088933
Tanespimycin in Treating Patients With Stage III-IV Melanoma
NCT00087386
Genetic and Protein Profiling in Normal and Cancerous Breast Tissue
NCT00083733
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
NCT00085553
Breast Cancer, Breast Disease, and Pesticides
NCT00341315
PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy
NCT00082368
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00086944
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00086827
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
NCT00077363
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
NCT00087217
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
NCT00085293
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
NCT00084630
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
NCT00085358
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
NCT00084643
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
NCT00087204
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00086840
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
NCT00086983
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
NCT00087191
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
NCT00080535
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer
NCT00082147
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
NCT00081848
Early Detection of Barrett's Esophagus
NCT00081354
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
NCT00082017
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00084916
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00079352
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.